Genome & Company (KOSDAQ:314130)

Genome & Company Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	36,133	65,549	56,356	72,216	36,049	103,948
Short-Term Investments	12,700	8,227	18,863	28,205	35,249	5,640
Trading Asset Securities	4,218	7,155	11,053	6,278	5,865	-
Cash & Short-Term Investments	53,051	80,930	86,272	106,699	77,164	109,588
Cash Growth	-32.17%	-6.19%	-19.14%	38.28%	-29.59%	257.85%
Accounts Receivable	2,865	2,060	1,402	1,957	759.22	-
Other Receivables	150.58	382.72	1,544	864.23	992.14	1,377
Receivables	3,015	2,442	2,946	2,821	1,751	1,377
Inventory	5,870	5,771	3,568	2,238	1,327	-
Prepaid Expenses	1,349	690.72	1,150	1,159	1,102	243.77
Other Current Assets	990.93	2,094	3,114	3,994	433.15	71.28
Total Current Assets	64,277	91,928	97,050	116,909	81,777	111,280
Property, Plant & Equipment	20,833	27,870	34,624	21,526	16,475	4,271
Long-Term Investments	0	-	-	-	-	-
Goodwill	14,133	14,133	14,133	16,458	16,458	1,063
Other Intangible Assets	6,084	8,256	11,102	13,921	18,388	3,811
Other Long-Term Assets	31,421	5,148	5,152	4,182	4,119	457.17
Total Assets	136,748	147,335	162,060	172,997	137,216	120,883
Accounts Payable	788.65	481.2	340.19	205.18	321.4	-
Accrued Expenses	977.56	1,729	2,723	3,428	1,713	316.7
Short-Term Debt	14,961	18,401	12,634	-	-	-
Current Portion of Leases	1,237	1,228	1,055	2,024	1,583	580.26
Other Current Liabilities	6,295	7,973	12,131	5,484	6,208	2,111
Total Current Liabilities	33,259	29,812	28,883	11,141	9,826	3,008
Long-Term Debt	-	9,000	9,000	-	-	-
Long-Term Leases	2,571	3,395	3,764	4,267	5,243	1,179
Long-Term Deferred Tax Liabilities	2,615	3,242	4,414	5,582	6,826	782.66
Other Long-Term Liabilities	2,936	2,820	2,482	1,462	1,921	830.66
Total Liabilities	41,381	48,270	48,543	22,452	23,816	5,800
Common Stock	15,543	15,527	7,363	7,046	7,033	6,652
Additional Paid-In Capital	304,621	296,475	304,765	304,724	257,345	246,880
Retained Earnings	-325,805	-304,771	-284,659	-237,193	-185,355	-151,238
Comprehensive Income & Other	86,598	40,198	34,240	21,784	13,710	9,139
Total Common Equity	80,957	47,428	61,708	96,360	92,733	111,434
Minority Interest	8,900	50,753	51,089	53,248	20,667	3,371
Shareholders' Equity	95,367	99,065	113,517	150,544	113,400	115,083
Total Liabilities & Equity	136,748	147,335	162,060	172,997	137,216	120,883
Total Debt	27,769	32,024	26,453	6,291	6,826	1,759
Net Cash (Debt)	25,282	48,906	59,819	100,408	70,338	107,829
Net Cash Growth	-46.94%	-18.24%	-40.42%	42.75%	-34.77%	364.28%
Net Cash Per Share	630.33	1605.36	2118.26	3566.88	2616.46	5599.59
Filing Date Shares Outstanding	33.16	31.05	29.45	28.18	28.13	26.61
Total Common Shares Outstanding	33.16	31.05	29.45	28.18	28.13	26.61
Working Capital	31,017	62,115	68,167	105,769	71,952	108,272
Book Value Per Share	2441.56	1527.27	2095.34	3419.08	3296.30	4187.69
Tangible Book Value	60,740	25,040	36,473	65,981	57,888	106,559
Tangible Book Value Per Share	1831.83	806.31	1238.47	2341.16	2057.68	4004.50
Land	1,819	2,699	2,710	10.59	-	-
Buildings	6,212	9,251	9,220	-	-	-
Machinery	17,418	18,063	15,838	14,662	9,167	3,026
Construction In Progress	2,641	2,503	8,492	4,245	2,262	19.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.